Frankfurt
21.11.24
15:29 Uhr
3,440 Euro
-0,060
-1,71 %
-1,71 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 12.11. | Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | 113 | GlobeNewswire (Europe) | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory... ► Artikel lesen | |
| 11.10. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 11.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.09. | Nanobiotix reports 1H results | 2 | Seeking Alpha | ||
| 18.09. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results | 187 | GlobeNewswire (Europe) | RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune... ► Artikel lesen | |
| 18.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.09. | Nanobiotix S.A.: NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth | 3 | GlobeNewswire (USA) | ||
| 03.09. | Nanobiotix S.A.: Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 03.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | Nanobiotix shares rated Buy by Guggenheim, focused on expanding cancer treatment applications | 1 | Investing.com | ||
| 09.07. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 09.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.06. | Nanobiotix S.A.: NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 | 5 | GlobeNewswire (USA) | ||
| 11.06. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 11.06. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.06. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.06. | Nanobiotix S.A.: Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy | 222 | GlobeNewswire (Europe) | Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later... ► Artikel lesen | |
| 28.05. | Nanobiotix S.A.: NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call | 3 | GlobeNewswire (USA) | ||
| 21.05. | Nanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth | 337 | GlobeNewswire (Europe) | Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorship... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| PALATIN TECHNOLOGIES | 0,865 | +0,70 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | 0,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 42,860 | -1,31 % | Evotec: Halozyme-Offerte über 11 Euro wirft Fragen auf | Übernahmegerüchte gibt es bei Evotec schon länger. Mit dem Auftauchen des Evotec-Aktienpaketes bei Triton, wir berichteten, schien eigentlich klar, wer der mögliche Kandidat für den zukünftigen Mehrheitsaktionär... ► Artikel lesen | |
| GLOW LIFETECH | 0,029 | -7,94 % | Glow LifeTech Corp.: Glow Lifetech Announces Non-Brokered Private Placement Offering of Units and Debt Settlement | Toronto, Ontario--(Newsfile Corp. - November 5, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it intends to complete a non-brokered... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,500 | -1,50 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 309,90 | +0,91 % | Bio-Rad Reports Third-Quarter 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 11,500 | 0,00 % | Avid Bioservices, Inc. (CDMO): A Bull Case Theory | ||
| BIOLINERX | 0,326 | -37,31 % | BioLineRx inks licensing deal, share purchase agreement | ||
| MINERVA NEUROSCIENCES | 1,980 | -2,94 % | Aktie von Minerva Neurosciences erreicht 52-Wochen-Tief bei 2,25 US-Dollar | ||
| GEOVAX LABS | 2,685 | 0,00 % | GeoVax meldet Fortschritte bei Studie zu CLL-Impfstoff-Booster | ||
| AADI BIOSCIENCE | 2,060 | -2,83 % | Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update | FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth
Aadi continues to focus on FYARRO commercial business and comprehensive strategic... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 8,835 | -4,49 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,940 | -5,53 % | Ovid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth | NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,71 % bei einem Aktienkurs von 3,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.
